On April 25, 2026, EG BioMed proudly renewed its support as both a sponsor and an active participant in PurpleStride 2026, the nationwide walk organized by the Pancreatic Cancer Action Network (PanCAN). Walking alongside survivors, families, healthcare professionals, and researchers, our team stood united in a shared mission: to elevate public awareness of pancreatic cancer […]
YD Bio Limited has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery.
EG BioMed today announced a pivotal advancement in its global intellectual property portfolio. The company’s breakthrough technology for breast cancer monitoring has officially been granted patent certificates by the patent offices of Japan and South Korea, marking a significant achievement in EG BioMed’s ongoing commitment to delivering innovative diagnostic solutions to the international market. Advancing
The four-day Healthcare+ Expo Taiwan has successfully come to an end! We extend our sincere gratitude to every physician, researcher, industry partner, and health-conscious visitor who visited our booth. The insightful discussions we shared underscore our collective mission to transform the future of healthcare. Transforming Cancer Care Through Innovation At EG BioMed US, we are
Healthcare+ Expo Taiwan: Advancing Global Cancer Detection with OkaiDx™ Read More »
EG BioMed is proud to announce that we have been awarded the prestigious “Enterprise Innovation Award” at the 22nd National Innovation Awards. Our pioneering pancreatic cancer blood detection technology has once again earned major recognition for its breakthrough potential in the field of oncology. Pancreatic cancer is notoriously difficult to diagnose in its early stages
We are proud to announce that EG BioMed’s Washington Laboratory has successfully passed the on-site inspection by the College of American Pathologists (CAP), earning official CAP accreditation — a globally recognized mark of laboratory excellence. Note 1：The College of American Pathologists (CAP) is the world’s largest organization of board-certified pathologists, focused on laboratory quality and
EG BioMed US Inc. Earns International CAP Accreditation Read More »
EG BioMed was honored with two major accolades in the SME category at the 23rd Golden Peak Awards: “Top 10 Outstanding Leaders” and “Top 10 in Innovation and R&D”. At the award ceremony held on April 25, 2025, Chairman Hsieh-Tsung Shen accepted the honors on behalf of the company, marking an important recognition from the
EG BioMed is excited to participate in BIO Asia–Taiwan 2025, one of Asia’s most influential biotech events, taking place from July 24 to 27 at the Taipei Nangang Exhibition Center, Hall 1 (4th Floor). BIO Asia–Taiwan Exhibition 2025 Booth Map – EG BioMed @ BIO Asia–Taiwan 2025 About EG BioMed EG BioMed is dedicated to
Join EG BioMed at BIO Asia–Taiwan 2025! Read More »
In 2025, EG BioMed presented its ZFP30-targeting cfDNA methylation blood test, the EG-Pancreatic Blood Test-E1, at the ASCO Annual Meeting. The test demonstrated promising early detection results for pancreatic cancer, particularly among the Western population. This study builds on findings we shared at the AACR Annual Meeting in April 20251, where ZFP30 and ZNF781 were
Enhancing Prognostic Precision: The Role of TMEM240 Methylation in Colorectal Cancer Limitations of Current Testing Methods Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally. Traditional blood-based markers like CEA and CA19-9 often lack the sensitivity and timeliness needed to detect early disease progression or treatment response. There is a clear unmet need
